{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:52:17Z","timestamp":1785466337935,"version":"3.56.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.vaccine.2012.10.070","type":"journal-article","created":{"date-parts":[[2012,10,30]],"date-time":"2012-10-30T20:32:07Z","timestamp":1351629127000},"page":"850-856","source":"Crossref","is-referenced-by-count":45,"title":["PER.C6\u00ae cells as a serum-free suspension cell platform for the production of high titer poliovirus: A potential low cost of goods option for world supply of inactivated poliovirus vaccine"],"prefix":"10.1016","volume":"31","author":[{"given":"Barbara P.","family":"Sanders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Edo-Matas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome H.H.V.","family":"Custers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H.","family":"Koldijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Klaren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marije","family":"Turk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Luitjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried A.M.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fons","family":"Uytdehaag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap","family":"Goudsmit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke","family":"Schuitemaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5666","key":"10.1016\/j.vaccine.2012.10.070_bib0005","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.303.5666.1960","article-title":"Polio endgame. Polio: the final assault?","volume":"303","author":"Roberts","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2012.10.070_bib0010","unstructured":"WHO. Polio this week: <http:\/\/www.polioeradication.org\/Dataandmonitoring\/Poliothisweek.aspx>. Consulted October 2012."},{"issue":"11","key":"10.1016\/j.vaccine.2012.10.070_bib0015","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1001\/jama.1957.62980110008008","article-title":"Properties and behavior of orally administered attenuated poliovirus vaccine","volume":"164","author":"Sabin","year":"1957","journal-title":"JAMA"},{"issue":"39","key":"10.1016\/j.vaccine.2012.10.070_bib0020","doi-asserted-by":"crossref","first-page":"4978","DOI":"10.1016\/j.vaccine.2008.07.026","article-title":"World wide experience with inactivated poliovirus vaccine","volume":"26","author":"Bonnet","year":"2008","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2012.10.070_bib0025","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1586\/14760584.8.1.5","article-title":"Role of injectable and oral polio vaccines in polio eradication","volume":"8","author":"John","year":"2009","journal-title":"Expert Rev Vaccines"},{"issue":"5566","key":"10.1016\/j.vaccine.2012.10.070_bib0030","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1126\/science.1068284","article-title":"Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus","volume":"296","author":"Kew","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2012.10.070_bib0035","first-page":"1335","article-title":"Paralytic disease associated with oral Polio vaccines","volume":"13","author":"Henderson","year":"1964","journal-title":"JAMA"},{"issue":"5370","key":"10.1016\/j.vaccine.2012.10.070_bib0040","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1136\/bmj.2.5370.1468-c","article-title":"Immunity to poliomyelitis","volume":"2","author":"Dick","year":"1963","journal-title":"Br Med J"},{"issue":"11","key":"10.1016\/j.vaccine.2012.10.070_bib0045","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/aje\/kwq320","article-title":"From emergence to eradication: the epidemiology of poliomyelitis deconstructed","volume":"172","author":"Nathanson","year":"2010","journal-title":"Am J Epidemiol"},{"issue":"20","key":"10.1016\/j.vaccine.2012.10.070_bib0050","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.vaccine.2009.02.071","article-title":"Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication","volume":"27","author":"Minor","year":"2009","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2012.10.070_bib0055","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.3390\/v3081460","article-title":"Recombination between poliovirus and coxsackie A viruses of species C: a model of viral genetic plasticity and emergence","volume":"3","author":"Combelas","year":"2011","journal-title":"Viruses"},{"issue":"15","key":"10.1016\/j.vaccine.2012.10.070_bib0060","first-page":"137","article-title":"Inactivated poliovirus vaccine following oral poliovirus vaccine cessation","volume":"81","author":"WHO","year":"2006","journal-title":"Wkly Epidemiol Rec"},{"issue":"5","key":"10.1016\/j.vaccine.2012.10.070_bib0065","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2105\/AJPH.44.5.563","article-title":"Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines","volume":"44","author":"Salk","year":"1954","journal-title":"Am J Public Health Nations Health"},{"key":"10.1016\/j.vaccine.2012.10.070_bib0070","first-page":"197","article-title":"Anomalous observations on IPV and OPV vaccination","volume":"105","author":"John","year":"2001","journal-title":"Dev Biol (Basel)"},{"issue":"8591","key":"10.1016\/j.vaccine.2012.10.070_bib0075","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0140-6736(88)91711-4","article-title":"Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine","volume":"1","author":"Robertson","year":"1988","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2012.10.070_bib0080","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2165\/11206690-000000000-00000","article-title":"Spotlight on DTPa-HBV-IPV\/Hib vaccine (Infanrix hexa)","volume":"24","author":"Dhillon","year":"2010","journal-title":"BioDrugs"},{"issue":"22","key":"10.1016\/j.vaccine.2012.10.070_bib0085","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1016\/j.vaccine.2010.02.095","article-title":"The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox","volume":"28","author":"Heinsbroek","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.10.070_bib0090","series-title":"An economic analysis of strategies to reduce the cost of routine IPV immunization","article-title":"Improving the affordability of inactivated poliovirus vaccines (IPV) for use in low- and middle-income countries","author":"Zehrung","year":"2010"},{"issue":"5","key":"10.1016\/j.vaccine.2012.10.070_bib0095","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1586\/erv.09.19","article-title":"Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines","volume":"8","author":"Barrett","year":"2009","journal-title":"Expert Rev Vaccines"},{"issue":"13","key":"10.1016\/j.vaccine.2012.10.070_bib0100","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1089\/hum.1998.9.13-1909","article-title":"New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses","volume":"9","author":"Fallaux","year":"1998","journal-title":"Hum Gene Ther"},{"issue":"17\u201319","key":"10.1016\/j.vaccine.2012.10.070_bib0105","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1016\/S0264-410X(00)00508-9","article-title":"The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines","volume":"19","author":"Pau","year":"2001","journal-title":"Vaccine"},{"issue":"39\u201340","key":"10.1016\/j.vaccine.2012.10.070_bib0110","doi-asserted-by":"crossref","first-page":"6872","DOI":"10.1016\/j.vaccine.2007.07.011","article-title":"A sensitive cell-based assay for the detection of residual infectious West Nile virus","volume":"25","author":"Koldijk","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.10.070_bib0115","article-title":"Per.C6 cells for the manufacture of biopharmaceutical proteins","volume":"vol. 3","author":"Yallop","year":"2005"},{"issue":"3","key":"10.1016\/j.vaccine.2012.10.070_bib0120","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/infdis\/151.3.420","article-title":"Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world","volume":"151","author":"Sabin","year":"1985","journal-title":"J Infect Dis"},{"issue":"467","key":"10.1016\/j.vaccine.2012.10.070_bib0125","article-title":"F.C. Alteration in pathogenicity for monkeys of the Brunhilde strain of Poliomyelitis virus following cultivation in human tissues","volume":"11","author":"Enders","year":"1952","journal-title":"Fed Proc"},{"key":"10.1016\/j.vaccine.2012.10.070_bib0130","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1021\/es60130a004","article-title":"Trimmed Spearman\u2013Karber method for estimating median lethal concentration in toxicity bioassays","volume":"11","author":"Hamilton","year":"1977","journal-title":"Environ Sci Technol"},{"key":"10.1016\/j.vaccine.2012.10.070_bib0135","first-page":"55","article-title":"The large-scale cultivation of VERO cells in micro-carrier culture for virus vaccine production. Preliminary results for killed poliovirus vaccine","volume":"47","author":"Montagnon","year":"1981","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.vaccine.2012.10.070_bib0140","first-page":"65","article-title":"Large-scale concentration and purification of virus suspension from microcarrier culture for the preparation of inactivated virus vaccines","volume":"42","author":"van Wezel","year":"1979","journal-title":"Dev Biol Stand"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2012.10.070_bib0145","doi-asserted-by":"crossref","first-page":"S335","DOI":"10.1093\/clinids\/6.Supplement_2.S335","article-title":"Inactivated poliovirus vaccine: current production methods and new developments","volume":"6","author":"van Wezel","year":"1984","journal-title":"Rev Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2012.10.070_bib0150","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/vim.1990.3.243","article-title":"Production of poliovirus vaccines: past, present, and future","volume":"3","author":"Duchene","year":"1990","journal-title":"Viral Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2012.10.070_bib0155","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/rmv.401","article-title":"Polio eradication: the OPV paradox","volume":"13","author":"Dowdle","year":"2003","journal-title":"Rev Med Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2012.10.070_bib0160","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.biologicals.2006.03.010","article-title":"Production, testing and perspectives of IPV and IPV combination vaccines: GSK biologicals\u2019 view","volume":"34","author":"Duchene","year":"2006","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2012.10.070_bib0165","unstructured":"Venczel L, Landry S, Aylward B, Sutter R, Sabow A, Smith G. Global post-eradication IPV supply and demand assessment: integrated findings \u2013 commissioned by the Bill & Melinda Gates foundation. Oliver Wyman, Inc.; 2009."},{"issue":"25","key":"10.1016\/j.vaccine.2012.10.070_bib0170","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1056\/NEJMoa0909383","article-title":"Fractional doses of inactivated poliovirus vaccine in Oman","volume":"362","author":"Mohammed","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2012.10.070_bib0175","unstructured":"WHO. Update on improving IPV. The Polio Pipeline 2009;3:3."},{"key":"10.1016\/j.vaccine.2012.10.070_bib0180","first-page":"153","article-title":"Elimination of serum from cell culture medium","volume":"99","author":"Lubiniecki","year":"1999","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.vaccine.2012.10.070_bib0185","first-page":"157","article-title":"The development, benefits and disadvantages of serum-free media","volume":"99","author":"Froud","year":"1999","journal-title":"Dev Biol Stand"},{"issue":"2","key":"10.1016\/j.vaccine.2012.10.070_bib0190","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.biologicals.2006.02.011","article-title":"Technology transfer of Sabin-IPV to new developing country markets","volume":"34","author":"Kreeftenberg","year":"2006","journal-title":"Biologicals"},{"issue":"3","key":"10.1016\/j.vaccine.2012.10.070_bib0195","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF00749655","article-title":"High cell density perfusion cultures of anchorage-dependent Vero cells in a depth filter perfusion system","volume":"17","author":"Choi","year":"1995","journal-title":"Cytotechnology"},{"key":"10.1016\/j.vaccine.2012.10.070_bib0200","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.enzmictec.2004.11.008","article-title":"Comparison of various culture modes for the production of rabies virus by Vero cells grown on microcarriers in a 2-l bioreactor","volume":"36","author":"Trabelsi","year":"2005","journal-title":"Enzyme Microb Technol"},{"issue":"1","key":"10.1016\/j.vaccine.2012.10.070_bib0205","first-page":"1","article-title":"Structured model of VERO cells metabolism in a fixed-bed bioreactor","volume":"6","author":"Gelbgras","year":"2011","journal-title":"Chem Prod Process Model"},{"key":"10.1016\/j.vaccine.2012.10.070_bib0210","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1472-6750-11-81","article-title":"Serum-free microcarrier based production of replication deficient influenza vaccine candidate virus lacking NS1 using Vero cells","volume":"11","author":"Chen","year":"2011","journal-title":"BMC Biotechnol"},{"issue":"9","key":"10.1016\/j.vaccine.2012.10.070_bib0215","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1006\/cbir.1993.1152","article-title":"Protein-free culture of Vero cells: a substrate for replication of human pathogenic viruses","volume":"17","author":"Cinatl","year":"1993","journal-title":"Cell Biol Int"},{"issue":"1","key":"10.1016\/j.vaccine.2012.10.070_bib0220","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00253-009-2064-y","article-title":"A novel animal-component-free medium for rabies virus production in Vero cells grown on Cytodex 1 microcarriers in a stirred bioreactor","volume":"85","author":"Rourou","year":"2009","journal-title":"Appl Microbiol Biotechnol"},{"issue":"6","key":"10.1016\/j.vaccine.2012.10.070_bib0225","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/btpr.279","article-title":"Development of an animal-component free medium for Vero cells culture","volume":"25","author":"Rourou","year":"2009","journal-title":"Biotechnol Prog"},{"issue":"7213","key":"10.1016\/j.vaccine.2012.10.070_bib0230","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/S0140-6736(61)90843-1","article-title":"The D-antigen content in poliovaccine as a measure of potency","volume":"2","author":"Beale","year":"1961","journal-title":"Lancet"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12015307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12015307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T22:25:34Z","timestamp":1714515934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12015307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0264410X12015307"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.10.070","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}